ENTERA BIO LTD (ENTX) Stock Price & Overview

NASDAQ:ENTX • IL0011429839

Current stock price

1.27 USD
-0.05 (-3.79%)
Last:

The current stock price of ENTX is 1.27 USD. Today ENTX is down by -3.79%. In the past month the price decreased by -16.45%. In the past year, price decreased by -32.45%.

ENTX Key Statistics

52-Week Range1 - 3.22
Current ENTX stock price positioned within its 52-week range.
1-Month Range1.17 - 1.65
Current ENTX stock price positioned within its 1-month range.
Market Cap
58.242M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.13
Dividend Yield
N/A

ENTX Stock Performance

Today
-3.79%
1 Week
+1.60%
1 Month
-16.45%
3 Months
-41.20%
Longer-term
6 Months -29.44%
1 Year -32.45%
2 Years -23.95%
3 Years +9.48%
5 Years -66.67%
10 Years N/A

ENTX Stock Chart

ENTERA BIO LTD / ENTX Daily stock chart

ENTX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to ENTX. When comparing the yearly performance of all stocks, ENTX is a bad performer in the overall market: 90.96% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ENTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ENTX. While ENTX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ENTX Earnings

Next Earnings DateMar 27, 2026
Last Earnings DateNov 14, 2025
PeriodQ3 / 2025
EPS Reported-$0.07
Revenue Reported
EPS Surprise 23.75%
Revenue Surprise %

ENTX Forecast & Estimates

7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 703.15% is expected in the next year compared to the current price of 1.27.

For the next year, analysts expect an EPS growth of -14.24% and a revenue growth -69.78% for ENTX


Analysts
Analysts82.86
Price Target10.2 (703.15%)
EPS Next Y-14.24%
Revenue Next Year-69.78%

ENTX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ENTX Financial Highlights

Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 50% compared to the year before.


Income Statements
Revenue(TTM)124.00K
Net Income(TTM)-10.78M
Industry RankSector Rank
PM (TTM) N/A
ROA -61.93%
ROE -70.77%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.5%
Sales Q2Q%-100%
EPS 1Y (TTM)50%
Revenue 1Y (TTM)N/A

ENTX Ownership

Ownership
Inst Owners20.34%
Shares45.86M
Float34.54M
Ins Owners2.86%
Short Float %0.34%
Short Ratio0.53

ENTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8388.432B
AMGN AMGEN INC16.04197.413B
GILD GILEAD SCIENCES INC16.4179.993B
VRTX VERTEX PHARMACEUTICALS INC24.21119.226B
REGN REGENERON PHARMACEUTICALS15.9578.843B
ALNY ALNYLAM PHARMACEUTICALS INC42.0141.564B
INSM INSMED INC N/A30.069B
BIIB BIOGEN INC11.2926.644B
NTRA NATERA INC N/A26.624B
UTHR UNITED THERAPEUTICS CORP17.9523.498B
MRNA MODERNA INC N/A20.758B
EXAS EXACT SCIENCES CORP340.7419.77B
RVMD REVOLUTION MEDICINES INC N/A18.798B

About ENTX

Company Profile

ENTX logo image Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Company Info

IPO: 2018-06-28

ENTERA BIO LTD

Hadassah / Jerusalem Bio, Park, 5th Floor

JERUSALEM 9112002 IL

CEO: Spiros Jamas

Employees: 20

ENTX Company Website

ENTX Investor Relations

Phone: 97225327151

ENTERA BIO LTD / ENTX FAQ

What does ENTX do?

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.


Can you provide the latest stock price for ENTERA BIO LTD?

The current stock price of ENTX is 1.27 USD. The price decreased by -3.79% in the last trading session.


Does ENTERA BIO LTD pay dividends?

ENTX does not pay a dividend.


What is the ChartMill technical and fundamental rating of ENTX stock?

ENTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of ENTERA BIO LTD (ENTX)?

ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).


What is the market capitalization of ENTX stock?

ENTERA BIO LTD (ENTX) has a market capitalization of 58.24M USD. This makes ENTX a Micro Cap stock.


What is the next earnings date for ENTX stock?

ENTERA BIO LTD (ENTX) will report earnings on 2026-03-27, after the market close.